The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer
Open accessAbstract
BACKGROUND: Standard first-line therapy for metastatic, squamous non-small-cell lung cancer (NSCLC) is platinum-based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD-L1] expression on ≥50% of tumor cells). More recently, pembrolizumab plus chemotherapy was shown to significantly prolong overall survival among patients with nonsquamous NSCLC. METHODS: In this double-blind, phase 3 trial, we randomly assigned, in a 1:1 ratio, 559 patients with untreated metastatic, squamous NSCLC to receive 200 mg of pembrolizumab or saline placebo for up to 35 cycles; all the patients also received carboplatin and either paclitaxel or nanoparticle albumin-bound [nab]-paclitaxel for the first 4 cycles. Primary end points were overall survival and progression-free survival. RESULTS: After a median follow-up of 7.8 months, the median overall survival was 15.9 months (95% confidence interval [CI], 13.2 to not reached) in the pembrolizumab-combination group and 11.3 months (95% CI, 9.5 to 14.8) in the placebo-combination group (hazard ratio for death, 0.64; 95% CI, 0.49 to 0.85; P<0.001). The overall survival benefit was consistent regardless of the level of PD-L1 expression. The median progression-free survival was 6.4 months (95% CI, 6.2 to 8.3) in the pembrolizumab-combination group and 4.8 months (95% CI, 4.3 to 5.7) in the placebo-combination group (hazard ratio for disease progression or death, 0.56; 95% CI, 0.45 to 0.70; P<0.001). Adverse events of grade 3 or higher occurred in 69.8% of the patients in the pembrolizumab-combination group and in 68.2% of the patients in the placebo-combination group. Discontinuation of treatment because of adverse events was more frequent in the pembrolizumab-combination group than in the placebo-combination group (13.3% vs. 6.4%). CONCLUSIONS: In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in significantly longer overall survival and progression-free survival than chemotherapy alone. (Funded by Merck Sharp & Dohme; KEYNOTE-407 ClinicalTrials.gov number, NCT02775435 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“chemotherapy plus immune checkpoint blockade has been recently approved as the first-line regimen for NSCLC, including patients with KRAS mutations (45, 46).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [45]
In the citing paper
“Importantly, two remarkable phase III trials (KEYNOTE-189 and KEYNOTE-407) demonstrated that addition of pembrolizumab (Keytruda, anti-PD1) could significantly prolong the survival of NSCLC patients (45, 97).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [45]
In the citing paper
“The promising results from these studies have led to the approval of pembrolizumab in combination with chemotherapy (carboplatin-pemetrexed) for metastatic, non-squamous NSCLC, and the approval of pembrolizumab in combination with chemotherapy (carboplatin and Taxol) for patients with squamous lung carcinoma, excluding those carrying EGFR or ALK mutations.”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [45]
In the citing paper
“Toward this end, combinations of ICTs with concurrent and/or sequential chemotherapy are under extensive investigation, with phase III clinical data demonstrating overall survival and/or progression-free survival benefi t in NSCLC ( 63-66 ), small cell lung cancer ( 51,52 ), triple-negative breast cancer ( 67 ), bladder cancer ( 53 ), and head and neck squamous cell carcinoma ( 68 ).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [64]
In the citing paper
“Later, in two phase 3 clinical studies (KEYNOTE-189 and KEYNOTE-407), pembrolizumab combined with standard chemotherapy led to a better overall survival (OS) and PFS in NSCLC patients, relative to chemotherapy monotherapy [53, 54].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [54]
In the citing paper
“Moreover, ORR, median PFS, and median DOR reported for the two treatment arms were consistent with those reported in the KEYNOTE-189 and KEYNOTE-407 trials of pembrolizumab i.v.þ chemotherapy for the treatment of mNSCLC.22,23”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Self-citationNivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Self-citationPembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Self-citationHerbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Self-citationPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Self-citationRittmeyer, A., Barlési, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Cobo, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,718
Self-citationNivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801946 · Cited by 3,063
Self-citationFirst-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613493 · Cited by 2,503
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 901–1,000 of 1,006
Xiao, G., Liu, Z., Gao, X., Wang, H., Peng, H., Li, J., Yang, L., Duan, H., & Zhou, R. (2021) · Immunotherapy · doi:10.2217/imt-2020-0262 · Cited by 32
Research progress in immune checkpoint inhibitors for lung cancer in China
Gan, J., Huang, Y., Fang, W., & Zhang, L. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211029826 · Cited by 27
Thompson, N., Stewart, G. D., Welsh, S. J., Doherty, G. J., Robinson, M. J., Neville, B. A., Vervier, K., Harris, S. R., Adams, D. J., Dalchau, K. M., et al. (2022) · BMC Cancer · doi:10.1186/s12885-021-09156-x · Cited by 31
Tsang, E. S., Csizmók, V., Williamson, L. M., Pleasance, E., Topham, J. T., Karasinska, J. M., Titmuss, E., Schrader, K. A., Yip, S. S. F., Tessier‐Cloutier, B., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00368-x · Cited by 26
Cholesterol efflux pathways hinder KRAS-driven lung tumor progenitor cell expansion
Guilbaud, E., Barouillet, T., Ilié, M., Borowczyk, C., Ivanov, S., Sarrazy, V., Vaillant, N., Ayrault, M., Castiglione, A., Rignol, G., et al. (2023) · Cell stem cell · doi:10.1016/j.stem.2023.05.005 · Cited by 28
Grodzka, A., Knopik-Skrocka, A., Kowalska, K., Kurzawa, P., Krzyżaniak, M., Stencel, K. M., & Bryl, M. (2023) · EXCLI journal · doi:10.17179/excli2023-6122 · Cited by 29
Tagliamento, M., Genova, C., Rossi, G., Coco, S., Rijavec, E., Bello, M. G. D., Boccardo, S., Grossi, F., & Alama, A. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1627326 · Cited by 29
Hao, J., Wang, H., Song, L., Li, S., Che, N., Zhang, S., Zhang, H., & Wang, J. (2020) · PubMed Central · Cited by 29
Toxicities associated with immune checkpoint inhibitors: a systematic study
Kong, X., Chen, L., Su, Z., Sullivan, R. J., Blum, S. M., Qi, Z., Liu, Y., Huo, Y., Fang, Y., Zhang, L., et al. (2023) · International Journal of Surgery · doi:10.1097/js9.0000000000000368 · Cited by 31
Morita, A., Ichihara, E., Inoue, K., Fujiwara, K., Yokoyama, T., Harada, D., Ando, C., Kano, H., Oda, N., Tamura, T., et al. (2024) · International Journal of Cancer · doi:10.1002/ijc.34842 · Cited by 29
Vallejo, J. J., Singh, H., Larkins, E. A., Drezner, N. L., Ricciuti, B., Mishra-Kalyani, P. S., Tang, S. W., Beaver, J. A., & Awad, M. M. (2024) · The Oncologist · doi:10.1093/oncolo/oyae006 · Cited by 27
del Socorro, T. P., Oka, K., Boulard, O., Takahashi, M., Poulin, L. F., Hayashi, A., & Chamaillard, M. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2315631 · Cited by 30
Polcaro, G., Liguori, L., Manzo, V., Chianese, A., Donadio, G., Caputo, A., Scognamiglio, G., Dell’Annunziata, F., Langella, M., Corbi, G., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01976-2 · Cited by 29
Ismail, A., Desai, A. P., & Boumber, Y. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1624124 · Cited by 31
Ascierto, P. A., Bifulco, C. B., Buonaguro, L., Emens, L. A., Ferris, R. L., Fox, B. A., Delgoffe, G. M., Galon, J., Gridelli, C., Merlano, M. C., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0798-3 · Cited by 28
Tun, A. M., Thein, K. Z., Thein, W. L., & Guevara, E. (2019) · Future Science OA · doi:10.2144/fsoa-2019-0081 · Cited by 28
PD-1 immunotherapy for recurrent or metastatic HNSCC
Ferris, R. L., & Licitra, L. F. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32539-5 · Cited by 28
Chen, J. A., Ma, W., Yuan, J. D., & Li, T. (2020) · Cancer treatment and research · doi:10.1007/978-3-030-38862-1_9 · Cited by 29
Nomura, S., Goto, Y., Mizutani, T., Kataoka, T., Kawai, S., Okuma, Y., Murakami, H., Tanaka, K., & Ohe, Y. (2020) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaa054 · Cited by 28
Guo, X., Li, W., Hu, J., Zhu, E. C., & Su, Q. (2020) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-02903-2 · Cited by 28
García, J., Bañobre, J. R., Afonso-Afonso, F. J., Amenedo, M., Manrique, M. C. A., Campos, B., Casal‐Rubio, J., Núñez, N. F., Pérez, J. L. F., Lázaro-Quintela, M., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072093 · Cited by 28
Xia, W.-Y., Feng, W., Zhang, C., Shen, Y., Zhang, Q., Yu, W. J., Cai, X., & Fu, X. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-827 · Cited by 30
Dong, A., Zhao, Y., Li, Z., & Hu, H. (2020) · The Journal of Gene Medicine · doi:10.1002/jgm.3294 · Cited by 29
Vekens, K., Everaert, H., Neyns, B., Ilsen, B., & Decoster, L. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.03.001 · Cited by 31
García-Fernández, C., Saz, A., Fornaguera, C., & Borrós, S. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00333-5 · Cited by 30
Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small Cell Lung Cancer
Shukla, N. A., & Hanna, N. H. (2021) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s277717 · Cited by 30
Gross, D., Chintala, N. K., Vaghjiani, R. G., Grosser, R., Tan, K. S., Li, X., Choe, J. K., Li, Y., Aly, R. G. M., Emoto, K., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.09.009 · Cited by 28
Self-citationZhang, X., Beachler, D. C., Masters, E. T., Liu, F., Yang, M., Dinh, J., Jamal‐Allial, A., Kolitsopoulos, F. M., & Lamy, F.-X. (2021) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2021.21216 · Cited by 29
Complications following novel therapies for non‐small cell lung cancer
Skribek, M., Rounis, K., Tsakonas, G., & Ekman, S. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13445 · Cited by 28
Cefalì, M., Epistolio, S., Ramelli, G., Mangan, D., Molinari, F., Martin, V., Freguia, S., Mazzucchelli, L., Froesch, P., Frattini, M., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11061627 · Cited by 28
Carroll, R., Bortolini, M., Calleja, A., Munro, R. E. J., Kong, S., Daumont, M., Penrod, J. R., Lakhdari, K., Lacoin, L., & Cheung, W. Y. (2022) · BMC Cancer · doi:10.1186/s12885-022-09342-5 · Cited by 28
Madala, S., Rasul, R., Singla, K., Sison, C. P., Seetharamu, N., & Castellanos, M. R. (2022) · Clinical Oncology · doi:10.1016/j.clon.2022.03.010 · Cited by 29
Montella, M., Sabetta, R., Ronchi, A., SIO, M. D., Arcaniolo, D., Vita, F. D., Tirino, G., Caputo, A., D’Antonio, A., Fiorentino, F., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.874213 · Cited by 27
Nie, W., Wang, Z., Zhang, K., Li, B., Cai, Y., Wen, F., Zhang, D., Bai, Y., Zhang, X., Wang, S., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02360-x · Cited by 28
Shah, N. J., Cook, M. R., Wu, T., Ari, S. L., Blackburn, M. J., Serzan, M. T., Alaoui, A., Ahn, J., & Atkins, M. B. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.7020 · Cited by 30
Zhang, Q., Gong, X., Sun, L., Miao, L., & Zhou, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.791496 · Cited by 29
Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity
Bylsma, S. A., Yun, K. M., Patel, S. P., & Dennis, M. J. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-00995-9 · Cited by 29
Lin, E. P.-Y., Hsu, C., Berry, L. D., Bunn, P. A., & Shyr, Y. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.27211 · Cited by 29
Gridelli, C., Peters, S., Velcheti, V., Attili, I., & de Marinis, F. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101192 · Cited by 30
Huang, Y., Xie, W.-J., Fan, H., & Du, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00972 · Cited by 29
Leapman, M., Presley, C. J., Zhu, W., Soulos, P. R., Adelson, K. B., Miksad, R. A., Boffa, D. J., & Gross, C. P. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.7205 · Cited by 28
Lema, D. A., Jankowska−Gan, E., Sethakorn, N., Burlingham, W. J., & Leal, T. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000152 · Cited by 27
Karim, N. A., & Kelly, K. L. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0112 · Cited by 26
Luo, H., Zhang, L., Yang, B., Feng, Y., Xiong, Y., Zhang, S., Li, X., Qian, C., Dong, W., & Dai, N. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00828-x · Cited by 27
Self-citationSakata, Y., Kawamura, K., Ichikado, K., Shingu, N., Yasuda, Y. U., Eguchi, Y., Hisanaga, J., Nitawaki, T., Iio, M., Sekido, Y., et al. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13214 · Cited by 27
Genomics models in radiotherapy: From mechanistic to machine learning
Kang, J., Coates, J. T. T., Strawderman, R. L., Rosenstein, B. S., & Kerns, S. L. (2020) · Medical Physics · doi:10.1002/mp.13751 · Cited by 28
Analysis of Immune Checkpoint Drug Targets and Tumor Proteotypes in Non-Small Cell Lung Cancer
Liebler, D. C., Holzer, T. R., Haragan, A., Morrison, R. D., Reising, L. O., Ackermann, B. L., Fill, J. A., Schade, A. E., & Gruver, A. M. (2020) · Scientific Reports · doi:10.1038/s41598-020-66902-0 · Cited by 28
Liang, J., Li, M., Sui, Q., Hu, Z., Bian, Y., Huang, Y., Zhan, C., Jiang, W., Wang, Q., & Tan, L. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-192 · Cited by 27
Kartolo, A., Feilotter, H. E., Hopman, W. M., Fung, A. S., & Robinson, A. G. (2021) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2021.100330 · Cited by 27
Checkpoint blockade toxicities: Insights into autoimmunity and treatment
Walsh, M. J., & Dougan, M. L. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101473 · Cited by 27
Majem, M., Cobo, M., Isla, D., Márquez-Medina, D., Rodríguez‐Abreu, D., Casal‐Rubio, J., Morán, T., Bernabé, R., Pérez-Parente, D., Gracia, P. R., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10071365 · Cited by 28
Self-citationSands, J. M., Mandrekar, S. J., Kozono, D., Oxnard, G. R., Hillman, S. L., Wigle, D. A., Govindan, R., Carlisle, J. W., Gray, J. E., Salama, J. K., et al. (2021) · Immunotherapy · doi:10.2217/imt-2021-0019 · Cited by 27
The changing landscape of anti-lung cancer drug clinical trials in mainland China from 2005 to 2020
Zhong, Q., Tao, Y., Chen, H., Zhou, Y. L., Huang, L., Han, X., & Shi, Y. (2021) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2021.100151 · Cited by 27
Li, J., Wang, J.-H., Dingv, Y., Li, D., Wen, X., Zhao, J., Jiang, H., Liu, X., Huang, F., & Zhang, X. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03700-9 · Cited by 27
The landscape of immune checkpoint inhibitor therapy in advanced lung cancer
Wang, C., Li, J., Zhang, Q., Wu, J., Xiao, Y., Song, L., Gong, H., & Li, Y. (2021) · BMC Cancer · doi:10.1186/s12885-021-08662-2 · Cited by 27
Nanobodies Enhancing Cancer Visualization, Diagnosis and Therapeutics
Naidoo, D. B., & Chuturgoon, A. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189778 · Cited by 28
Gu, J., Shi, L., Jiang, X., Wen, J., Zheng, X., Hu, C., & Zhang, W. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03140-5 · Cited by 27
Nakahama, K., Kaneda, H., Osawa, M., Izumi, M., Yoshimoto, N., Sugimoto, A. K., Nagamine, H., Ogawa, K., Matsumoto, Y., Sawa, K., et al. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14560 · Cited by 27
Bredin, P., & Naidoo, J. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10039-1 · Cited by 28
Tobacco Use and Response to Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer
Corke, L., Li, J. J. N., Leighl, N. B., & Eng, L. (2022) · Current Oncology · doi:10.3390/curroncol29090492 · Cited by 27
Lu, Y., Zhang, X., Ning, J., & Zhang, M. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2169531 · Cited by 28
Sun, B., Xun, Z., Zhang, N., Liu, K., Chen, X., & Zhao, H. (2023) · Cancer Cell International · doi:10.1186/s12935-023-03158-4 · Cited by 31
Huang, Y., Yang, Y., Zhao, Y., Zhao, H., Zhou, N., Zhang, Y., Chen, L., Zhou, T., Chen, G., Wu, T., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01731-x · Cited by 26
Huo, Y., Wang, D., Yang, S., Xu, Y., Qin, G., Zhao, C., Lei, Q., Zhao, Q., Liu, Y., Guo, K., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009627 · Cited by 26
Yao, J., Li, S., Bai, L., Chen, J., Ren, C., Liu, T., Qiu, J., & Dang, J. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103081 · Cited by 28
Hong, S., Wang, Q. J., Cheng, Y., Luo, Y., Qu, X., Zhu, H., Ding, Z., Li, X., Wu, L., Wang, Y., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03883-5 · Cited by 26
Self-citationJuergens, R. A., Hao, D., Ellis, P. M., Tu, D., Mates, M., Kollmannsberger, C., Bradbury, P. A., Tehfe, M., Wheatley‐Price, P., Robinson, A. G., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.02.016 · Cited by 26
Wang, W., Huang, Z., Yu, Z., Zhuang, W., Zheng, W., Cai, Z., Shi, L., Yu, X., Lou, G., Hong, W., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.572853 · Cited by 26
Addressing Resistance to Immune Checkpoint Inhibitor Therapy: An Urgent Unmet Need
Hu‐Lieskovan, S., Malouf, G. G., Jacobs, I. A., Chou, J., Liu, L., & Johnson, M. L. (2021) · Future Oncology · doi:10.2217/fon-2020-0967 · Cited by 26
Wang, L., Yang, Y., Yu, J., Zhang, S., Li, X., Wu, X., Nie, X., Liu, W., Zhang, P., Li, Y., et al. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.14244 · Cited by 26
Self-citationYoneda, T., Sone, T., Koba, H., Shibata, K., Suzuki, J., Tani, M., Nishitsuji, M., Nishi, K., Kobayashi, T., Shirasaki, H., et al. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.03.008 · Cited by 26
Cella, E., Zullo, L., Marconi, S., Rossi, G., Coco, S., Dellepiane, C., Alama, A., Rozeboom, L. M., Bennicelli, E., Parisi, F., et al. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2116273 · Cited by 25
Huang, J., Xiao, Y., Zhou, Y., Deng, H., Yuan, Z., Dong, L., Lan, J., Li, X., Liu, G., Hu, H., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-11312-4 · Cited by 26
Self-citationImmune-Related Toxicity in NSCLC: Current State-of-the-Art and Emerging Clinical Challenges
O’Leary, C. L., Pierce, N., Patel, S. P., & Naidoo, J. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.11.018 · Cited by 27
Immuno-Oncology—The New Paradigm of Lung Cancer Treatment
Dawe, D. E., Harlos, C. H., & Juergens, R. A. (2020) · Current Oncology · doi:10.3747/co.27.5183 · Cited by 26
Minari, R., Bonatti, F., Mazzaschi, G., Dodi, A., Facchinetti, F., Gelsomino, F., Cinquegrani, G., Squadrilli, A., Bordi, P., Buti, S., et al. (2021) · Tumori Journal · doi:10.1177/03008916211014954 · Cited by 25
Global research landscape and trends of lung cancer immunotherapy: A bibliometric analysis
Liu, Y., Xu, C., Han, X., Cheng, X., Jiang, S., Lin, Y., Zhang, Z., Lu, L., Qu, B., Chen, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1032747 · Cited by 27
Wang, H., Liu, F., Chen, X., Zhao, C., Li, X., Zhou, C., Hu, J., Chu, Q., & Jiang, T. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00412-3 · Cited by 25
Self-citationLiang, S., Wang, H., Tian, H., Xu, Z., Wu, M., Hua, D., & Li, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1249980 · Cited by 25
Reck, M., Barlési, F., Yang, J. C.-H., Westeel, V., Felip, E., Özgüroğlu, M., Cobo, M., Sullivan, R., Kowalski, D. M., Andric, Z. G., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.09.1445 · Cited by 27
Self-citationZhong, J., Fei, K., Wu, L., Li, B., Wang, Z., Cheng, Y., Li, X., Wang, X., Han, L., Wu, X., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02087-6 · Cited by 29
Self-citationCurrent Status of Immunotherapy for Lung Cancer and Future Perspectives
Kim, H. C., & Choi, C. (2019) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2019.0039 · Cited by 25
Chai, Q., Du, J., Zhu, J., & Wu, B. Y. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01260 · Cited by 25
Chen, Y., Seeruttun, S. R., Wu, X.-Y., & Wang, Z. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01432 · Cited by 25
Integration of immuno-oncology with stereotactic radiosurgery in the management of brain metastases
Lehrer, E. J., McGee, H. M., Sheehan, J. P., & Trifiletti, D. M. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03427-6 · Cited by 25
Reck, M., Syrigos, K., Miliauskas, S., Zöchbauer‐Müller, S., Fischer, J. R., Buchner, H., Kitzing, T. M., Kaiser, R., Radonjic, D., & Kerr, K. M. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.08.004 · Cited by 25
Wang, Y., Kong, D., Wang, C., Chen, J., Li, J., Liu, Z., Li, X., Wang, Z., Yao, G., & Wang, X. (2020) · Technology in Cancer Research & Treatment · doi:10.1177/1533033820967454 · Cited by 25
Self-citationSugisaka, J., Toi, Y., Taguri, M., Kawashima, Y., Aiba, T., Kawana, S., Saito, R., Aso, M., Tsurumi, K., Suzuki, K., et al. (2019) · JMA Journal · doi:10.31662/jmaj.2019-0005 · Cited by 25
Self-citationReal-world experience with pembrolizumab in patients with advanced soft tissue sarcoma
Liu, J., Fan, Z., Bai, C., Li, S., Xue, R., Gao, T., Zhang, L., Tan, Z., & Fang, Z. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-49 · Cited by 23
Mino-Kenudson, M. A., Stang, N. L., Daigneault, J. B., Nicholson, A. G., Cooper, W. A., Roden, A. C., Moreira, A. L., Thunnissen, E., Papotti, M. G., Pelosi, G., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.12.026 · Cited by 25
Nanotechnology synergized immunoengineering for cancer
Chauhan, D. S., Dhasmana, A., Laskar, P., Prasad, R., Jain, N. K., Srivastava, R., Jaggi, M., Chauhan, S. C., & Yallapu, M. M. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.03.010 · Cited by 27
Zhou, J., Zhao, J., Jia, Q., Chu, Q., Zhou, F., Chu, X., Zhao, W., Ren, S., Zhou, C., & Su, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.625578 · Cited by 26
Tang, M., Li, Y., Luo, X., Xiao, J., Wang, J., Zeng, X., Hu, Q.-H., Chen, X., Tan, S.-J., & Hu, J. X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.606106 · Cited by 26
Garon, E. B., Spira, A. I., Johnson, M. L., Bazhenova, L. A., Leach, J., Cummings, A. L., Candia, A. F., Coffman, R. L., Janatpour, M. J., Janssen, R. S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0263 · Cited by 25
Xu, Y., Wang, Q., Xie, J., Chen, M., Liu, H., Zhan, P., Lv, T., & Song, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.732214 · Cited by 25
Liao, G., Zhao, Z., Qian, Y., Ling, X., Chen, S., Li, X., & Kong, F. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.774131 · Cited by 26
Self-citationYamaguchi, T., Shimizu, J., Oya, Y., Watanabe, N., Hasegawa, T., Horio, Y., Inaba, Y., & Fujiwara, Y. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14308 · Cited by 24
O'Byrne, K. J., Lee, K. H., Kim, S.-W., Park, K., Nishio, M., Sakai, H., Ohe, Y., Fukuhara, T., Kang, J. H., Daga, H., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100394 · Cited by 25
Self-citationOlofsson, G. H., Mikkelsen, M. K., Ragle, A., Christiansen, A. B., Olsen, A. P., Heide-Ottosen, L., Horsted, C. B., Pedersen, C. M. S., Engell-Noerregaard, L., Lorentzen, T., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-09349-y · Cited by 30
Tensor Radiomics: Paradigm for Systematic Incorporation of Multi-Flavoured Radiomics Features
Rahmim, A., Toosi, A., Salmanpour, M. R., Dubljevic, N., Janzen, I., Shiri, I., Ramezani, M. A., Yuan, R., Ho, C., Zaidi, H., et al. (2022) · IEEE Nuclear Science Symposium and Medical Imaging Conference (NSS/MIC) · doi:10.1109/nss/mic44845.2022.10399050 · Cited by 25
Metadata
- Authors
- Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., Hermes, B., Çay Şenler, F., Csőszi, T., Fülöp, A., Rodríguez-Cid, J., Wilson, J., Sugawara, S., Kato, T., Lee, K. H., Cheng, Y., Novello, S., Halmos, B., Li, X., Lubiniecki, G. M., Piperdi, B., & Kowalski, D. M.
- Affiliations
- Université Toulouse III - Paul Sabatier (FR)
- From Hospital Universitario 12 de Octubre, Spanish National Cancer Research Center, Universidad Complutense and Ciberonc, Madrid (L.P.-A.), and Hospital Universitario Virgen Macarena, Seville (D.V.) — both in Spain; Leningrad Regional Clinical Hospital, St. Petersburg, Russia (A.L.); Wollongong Oncology and Wollongong Private Hospital, Wollongong, NSW, Australia (A.T.); Istanbul Medeniyet University Hospital, Istanbul (M.G.), and Ankara University, Ankara (F.Ç.Ş.) — both in Turkey; Centre...
- Ankara University (TR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-11-22
- Volume
- 379
- Issue
- 21
- Pages
- 2040-2051
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2892640821
- Cited by
- 3,617
- References
- 26
- Citations by year
- 2026: 220 · 2025: 328 · 2024: 445 · 2023: 440 · 2022: 565 · 2021: 630 · 2020: 606 · 2019: 361 · 2018: 16
- FWCI
- 303.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
- Funders
- Merck (N/A)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- pembrolizumab, lung squamous cell carcinoma, metastatic lung cancer, PD-L1 expression, immune checkpoint inhibitors, carboplatin, paclitaxel, nab-paclitaxel, first-line therapy, overall survival, progression-free survival, immune-related adverse events, treatment discontinuation, chemoimmunotherapy, PD-1 inhibitors
- MeSH terms
- Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Double-Blind Method, Female, Humans, Lung Neoplasms, Male, Middle Aged, Survival Analysis, Carboplatin, Paclitaxel, Intention to Treat Analysis, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
